文献速递免疫规划

福氏志贺菌2a结合疫苗在人体诱导2a型及交叉反应性6型抗体而在小鼠中不能

Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
PubMed 文献 · Vaccine · 2017-08-07

本研究分析既往研究中受试者血清,发现3-44岁人群注射福氏志贺菌2a结合疫苗后,20-30%出现抗6型IgG≥4倍升高(p<0.00001);2名儿童感染福氏志贺菌6型后也产生2a型抗体。小鼠对结合疫苗仅应答同型O-SP,无交叉反应抗体。

要点

  • 3-44岁受试者注射福氏志贺菌2a结合疫苗后,20-30%抗6型IgG升高≥4倍(p<0.00001)。
  • 2名儿童感染福氏志贺菌6型后诱导的2a型抗体水平与2a疫苗接种者相当。
  • 小鼠对结合疫苗几乎仅应答同型O-SP,未产生交叉反应抗体。

核心结论

  • 结果提示福氏志贺菌2a结合疫苗可诱导交叉反应性保护抗体。
  • 6型和2a型O-SP共享的O-乙酰化二糖可能是交叉反应基础。
  • 福氏志贺菌6型O-SP结合疫苗单独或与2a型联合值得进一步研究以提供广谱福氏志贺菌保护。

研究设计与样本

  • 检测既往研究中全部剩余血清的抗体。
  • 受试者包括3-44岁人群及2名感染福氏志贺菌6型的儿童。
  • 同时进行小鼠实验比较抗体应答。

主要发现

  • 3-44岁注射福氏志贺菌2a结合疫苗者中20-30%出现抗6型IgG≥4倍升高,p<0.00001。
  • 抑制研究证实这些抗体的特异性。
  • 2名儿童感染福氏志贺菌6型后诱导6型及2a型抗体,2a型抗体达2a疫苗接种者水平。
  • 小鼠对注射的结合疫苗几乎仅应答其O-SP,无交叉反应抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 既往1-4岁儿童效力研究中福氏志贺菌2a病例过少,不足以评估效力。
  • 未在人体评估福氏志贺菌6型结合疫苗诱导的2a型抗体,因无此类结合疫苗在人体的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Shigella flexneri (S. flexneri) 6 has emerged as an important cause of shigellosis. Our efficacy study of Shigella sonnei and S. flexneri 2a O-specific polysaccharide (O-SP) conjugates in 1-4year-olds had too few S. flexneri 2a cases for efficacy evaluation but surprisingly showed protection of 3-4year-olds, S. flexneri 2a-recipients, from S. flexneri 6 infection. To investigate this cross-protection antibodies to both Shigella types were investigated in all sera remaining from previous studies. Twenty to 30% of 3-44year-old humans injected with S. flexneri 2a conjugate responded with ≥4-fold increases of IgG anti type 6, p<0.00001. The specificity of these antibodies was shown by inhibition studies. S. flexneri 6 infection of 2 children induced besides S. flexneri 6, also S. flexneri 2a antibodies, at levels of S. flexneri 2a vaccinees. S. flexneri 2a antibodies induced by S. flexneri 6 conjugates could not be studied since no such conjugate was assessed in humans and mice responded almost exclusively to the O-SP of the injected conjugate, with no cross-reactive antibodies. Our results indicate induction of cross-reactive protective antibodies. The O-acetylated disaccharide shared by S. flexneri 6 and 2a O-SPs, is the likely basis for their cross-reactivity. S. flexneri 6 O-SP conjugates, alone and in combination with S. flexneri 2a, merit further investigation for broad S. flexneri protection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Farzam N, Ramon-Saraf R, Banet-Levi Y, et al. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice. Vaccine. 2017. PMID: 28797729. doi:10.1016/j.vaccine.2017.07.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。